Gαs is dispensable for β-arrestin coupling but dictates GRK selectivity and is predominant for gene expression regulation by β2-adrenergic receptor.

Autor: Burghi V; Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA., Paradis JS; Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA., Officer A; Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA., Adame-Garcia SR; Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA., Wu X; Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA., Matthees ESF; Institut für Molekulare Zellbiologie, CMB - Center for Molecular Biomedicine, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Jena, Germany., Barsi-Rhyne B; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, USA., Ramms DJ; Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA., Clubb L; Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA., Acosta M; Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA., Tamayo P; Moores Cancer Center, University of California San Diego, La Jolla, California, USA., Bouvier M; Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Québec, Canada., Inoue A; Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan., von Zastrow M; Department of Psychiatry and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California, USA., Hoffmann C; Institut für Molekulare Zellbiologie, CMB - Center for Molecular Biomedicine, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Jena, Germany., Gutkind JS; Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA. Electronic address: sgutkind@health.ucsd.edu.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2023 Nov; Vol. 299 (11), pp. 105293. Date of Electronic Publication: 2023 Sep 27.

Computationally designed GPCR quaternary structures bias signaling pathway activation.

Autor: Paradis JS; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, H3T 1J4, Canada.; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC, H3T 1J4, Canada., Feng X; Interfaculty Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, CH-1015, Switzerland.; Department of Structural Biology, Van Andel Institute, Grand Rapids, MI, USA., Murat B; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, H3T 1J4, Canada.; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC, H3T 1J4, Canada., Jefferson RE; Interfaculty Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, CH-1015, Switzerland., Sokrat B; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, H3T 1J4, Canada.; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC, H3T 1J4, Canada., Szpakowska M; Department of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg., Hogue M; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC, H3T 1J4, Canada., Bergkamp ND; Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit, Amsterdam, The Netherlands., Heydenreich FM; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, H3T 1J4, Canada.; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC, H3T 1J4, Canada., Smit MJ; Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit, Amsterdam, The Netherlands., Chevigné A; Department of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg., Bouvier M; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, H3T 1J4, Canada. michel.bouvier@umontreal.ca.; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC, H3T 1J4, Canada. michel.bouvier@umontreal.ca., Barth P; Interfaculty Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, CH-1015, Switzerland. patrick.barth@epfl.ch.

Publikováno v: Nature communications [Nat Commun] 2022 Nov 11; Vol. 13 (1), pp. 6826. Date of Electronic Publication: 2022 Nov 11.

Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ -Driven Uveal Melanoma.

Autor: Paradis JS; Moores Cancer Center, University of California San Diego, La Jolla, California., Acosta M; Moores Cancer Center, University of California San Diego, La Jolla, California., Saddawi-Konefka R; Moores Cancer Center, University of California San Diego, La Jolla, California.; Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of California San Diego, La Jolla, California., Kishore A; Moores Cancer Center, University of California San Diego, La Jolla, California., Gomes F; Moores Cancer Center, University of California San Diego, La Jolla, California., Arang N; Moores Cancer Center, University of California San Diego, La Jolla, California.; Biomedical Sciences Graduate Program, University of California San Diego, La Jolla, California., Tiago M; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania., Coma S; Verastem Oncology, Needham, Massachusetts., Lubrano S; Moores Cancer Center, University of California San Diego, La Jolla, California., Wu X; Moores Cancer Center, University of California San Diego, La Jolla, California., Ford K; Department of Bioengineering, University of California San Diego, San Diego, California., Day CP; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, NCI, NIH, Maryland., Merlino G; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, NCI, NIH, Maryland., Mali P; Department of Bioengineering, University of California San Diego, San Diego, California., Pachter JA; Verastem Oncology, Needham, Massachusetts., Sato T; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania., Aplin AE; Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania., Gutkind JS; Moores Cancer Center, University of California San Diego, La Jolla, California. sgutkind@ucsd.edu.; Department of Pharmacology, University of California San Diego, La Jolla, California.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jun 01; Vol. 27 (11), pp. 3190-3200. Date of Electronic Publication: 2021 Feb 10.

A new inhibitor of the β-arrestin/AP2 endocytic complex reveals interplay between GPCR internalization and signalling.

Autor: Beautrait A; Department of Biochemistry, Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec, Canada H3T 1J4., Paradis JS; Department of Molecular Biology Program, Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec, Canada H3T 1J4., Zimmerman B; Department of Pharmacology and Therapeutics, Research Institute of McGill University Health Centre (RI-MUHC), McGill University, Montréal, Quebec, Canada H4A 3J1., Giubilaro J; Department of Pharmacology and Therapeutics, Research Institute of McGill University Health Centre (RI-MUHC), McGill University, Montréal, Quebec, Canada H4A 3J1., Nikolajev L; Department of Medicine, Research Institute of McGill University Health Centre (RI-MUHC), McGill University, Montréal, Quebec, Canada H4A 3J1., Armando S; Department of Medicine, Research Institute of McGill University Health Centre (RI-MUHC), McGill University, Montréal, Quebec, Canada H4A 3J1., Kobayashi H; Department of Biochemistry, Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec, Canada H3T 1J4., Yamani L; Department of Medicine, Research Institute of McGill University Health Centre (RI-MUHC), McGill University, Montréal, Quebec, Canada H4A 3J1., Namkung Y; Department of Medicine, Research Institute of McGill University Health Centre (RI-MUHC), McGill University, Montréal, Quebec, Canada H4A 3J1., Heydenreich FM; Laboratory of Biomolecular Research, Department of Biology and Chemistry, Paul Scherrer Institut,5232 Villigen PSI, Switzerland, Switzerland., Khoury E; Department of Medicine, Research Institute of McGill University Health Centre (RI-MUHC), McGill University, Montréal, Quebec, Canada H4A 3J1., Audet M; Department of Biochemistry, Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec, Canada H3T 1J4., Roux PP; Department of Pathology and Cellular Biology, Institute of Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec, Canada H3T 1J4., Veprintsev DB; Laboratory of Biomolecular Research, Department of Biology and Chemistry, Paul Scherrer Institut,5232 Villigen PSI, Switzerland, Switzerland., Laporte SA; Department of Pharmacology and Therapeutics, Research Institute of McGill University Health Centre (RI-MUHC), McGill University, Montréal, Quebec, Canada H4A 3J1.; Department of Medicine, Research Institute of McGill University Health Centre (RI-MUHC), McGill University, Montréal, Quebec, Canada H4A 3J1.; Department of Anatomy and Cell Biology, Research Institute of McGill University Health Centre (RI-MUHC), McGill University, Montréal, Quebec, Canada H4A 3J1., Bouvier M; Department of Biochemistry, Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec, Canada H3T 1J4.

Publikováno v: Nature communications [Nat Commun] 2017 Apr 18; Vol. 8, pp. 15054. Date of Electronic Publication: 2017 Apr 18.

A biosensor to monitor dynamic regulation and function of tumour suppressor PTEN in living cells.

Autor: Lima-Fernandes E; 1] Department of Endocrinology, Metabolism and Diabetes, Inserm, U1016, Institut Cochin, 27 rue du Faubourg St Jaques, Paris 75014, France [2] CNRS, UMR8104, Paris 75014, France [3] University Paris Descartes, Sorbonne Paris Cité, Paris 75014, France [4]., Misticone S; 1] Department of Endocrinology, Metabolism and Diabetes, Inserm, U1016, Institut Cochin, 27 rue du Faubourg St Jaques, Paris 75014, France [2] CNRS, UMR8104, Paris 75014, France [3] University Paris Descartes, Sorbonne Paris Cité, Paris 75014, France [4]., Boularan C; 1] Department of Endocrinology, Metabolism and Diabetes, Inserm, U1016, Institut Cochin, 27 rue du Faubourg St Jaques, Paris 75014, France [2] CNRS, UMR8104, Paris 75014, France [3] University Paris Descartes, Sorbonne Paris Cité, Paris 75014, France [4]., Paradis JS; 1] Molecular Biology Program, Department of Biochemistry, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec, Canada H3C 3J7 [2] Department of Pathology and Cell Biology, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec, Canada H3C 3J7 [3]., Enslen H; 1] Department of Endocrinology, Metabolism and Diabetes, Inserm, U1016, Institut Cochin, 27 rue du Faubourg St Jaques, Paris 75014, France [2] CNRS, UMR8104, Paris 75014, France [3] University Paris Descartes, Sorbonne Paris Cité, Paris 75014, France., Roux PP; 1] Molecular Biology Program, Department of Biochemistry, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec, Canada H3C 3J7 [2] Department of Pathology and Cell Biology, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec, Canada H3C 3J7., Bouvier M; 1] Molecular Biology Program, Department of Biochemistry, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec, Canada H3C 3J7 [2] Department of Pathology and Cell Biology, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec, Canada H3C 3J7., Baillie GS; Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK., Marullo S; 1] Department of Endocrinology, Metabolism and Diabetes, Inserm, U1016, Institut Cochin, 27 rue du Faubourg St Jaques, Paris 75014, France [2] CNRS, UMR8104, Paris 75014, France [3] University Paris Descartes, Sorbonne Paris Cité, Paris 75014, France., Scott MG; 1] Department of Endocrinology, Metabolism and Diabetes, Inserm, U1016, Institut Cochin, 27 rue du Faubourg St Jaques, Paris 75014, France [2] CNRS, UMR8104, Paris 75014, France [3] University Paris Descartes, Sorbonne Paris Cité, Paris 75014, France.

Publikováno v: Nature communications [Nat Commun] 2014 Jul 16; Vol. 5, pp. 4431. Date of Electronic Publication: 2014 Jul 16.